Rapid Micro Biosystems Inc (NAS:RPID)

Q2 2026 Rapid Micro Biosystems, Inc Earnings Call Transcript

Aug 7, 2026 / 12:30 PM GMT

Release Date Price: $1.74 (-15.94%)

Transcript 10-Q8-K

Key Points

Positve

Rapid Micro Biosystems Inc (RPID) reported Q2 2026 total revenue of $8.1 million, an 11% year-over-year increase that exceeded guidance, driven by strong consumables growth of over 20% and a 14% increase in recurring revenue.
The company achieved significant milestones, including the placement of its 200th Growth Direct system and expectations to ship its 10 millionth consumable in Q3, highlighting growing adoption and routine use of its platform.
Gross margin improved significantly to a record 15% in Q2, up from 4% in the prior year, with expectations for Q4 gross margin to reach the mid-to-high 20% range, driven by successful margin expansion initiatives.
The partnership with Millipore Sigma is gaining traction, with their commercial organization contributing to system placements in the first half of 2026 and expected to contribute meaningfully more in the second half, expanding the company's commercial reach.
The company is seeing strong industry tailwinds, including increased demand for automation, US reshoring, and biomanufacturing capacity expansion, which are expected to become meaningful growth contributors starting in 2027.
Management reaffirmed full-year 2026 revenue guidance of $37-$41 million and increased full-year validation guidance to at least 27 systems, reflecting confidence in the business outlook.
The company executed a focused efficiency program expected to reduce expenses and cash usage by approximately $1 million in 2026 and $3 million annually starting in 2027, supporting its path to positive cash flow by the end of 2028.

Negative

Rapid Micro Biosystems Inc (RPID) reported a net loss of $12.9 million in Q2 2026, which was wider than the $11.9 million net loss in the same period last year, and adjusted EBITDA loss remained elevated at $10.3 million.
Product margin, which includes systems, software, and consumables, was slightly below expectations at 3% due to the timing of some software revenue that was pushed to the second half of the year.
The company's cash position remains tight at approximately $20 million, and it continues to rely on accessing future tranches of its debt facility with Trinity Capital to fund operations.
The contribution from the Millipore Sigma partnership is still in its early stages and will not fulfill its full contractual obligation for the calendar year, with a meaningful increase only expected in the second half.
Operating expenses increased to $13.5 million in Q2, up from $12.4 million in the prior year, driven by non-recurring corporate expenses, which partially offset the benefits of higher gross margins.
The company faces tough comparables in the second half of the year for consumables growth, with Q3 revenue expected to be relatively flat sequentially before a step-up in Q4.
Management noted that the benefits from US reshoring and biomanufacturing capacity expansion are not expected to materialize until mid-to-late 2027, indicating a longer wait for this growth driver.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RPID.OQ - Rapid Micro Biosystems, Inc.
Q2 2026 Rapid Micro Biosystems, Inc Earnings Call
Aug 07, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by.

Welcome to the Rapid Microbiosystem second quarter 2026 earnings conference call at this time, all participants are in a listen-only mode after the speaker's presentation, there will be a question-and-answer session to ask a question during the phone and here nod and made a message advising your hand is raised to withdraw your question, please press star 11 again.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Mike Bullier with Investor Relations, please go ahead, sir.

Good morning and thank you for joining the Rapid Micro Biosystems second quarter earnings call

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.